Phase II Evaluation of Bisantrene in Acute Leukemia
| Autor: | Glenn Mills, Charles A. Coltman, John D. Cowan, Barbara A. Neilan, Khadir Hussein, Steve Dahlberg, Conrad H. Gumbart |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Phases of clinical research Gastroenterology Drug Administration Schedule Internal medicine medicine Humans Aged Anthracenes Acute leukemia Chemotherapy Antibiotics Antineoplastic Leukemia Group study business.industry Remission Induction Middle Aged medicine.disease Surgery medicine.anatomical_structure Oncology Acute Disease Toxicity Drug Evaluation Female Bone marrow Bisantrene business |
| Zdroj: | American Journal of Clinical Oncology. 12:507-510 |
| ISSN: | 0277-3732 |
| Popis: | Twenty-nine patients with heavily pretreated acute leukemia in relapse were treated with bisantrene (maximum dose 120 mg/m2/day x 5) in a phase II study. Twenty-seven of the 29 patients were evaluable for response, receiving a total of 53 courses of treatment. There were three complete remissions (11%) lasting 27, 107, and 115 days. One brief partial remission of 43 days was also seen for a total response rate of 15%. Toxicity was mainly limited to the expected myelotoxicity with minimal nonhematologic toxicity seen. Although the complete remission rate is low, an antileukemic effect was seen in the majority of the patients treated. Sixty-one percent of the patients had at least a 50% decrease in the circulating blast count and 32% had at least a 50% decrease in the number of bone marrow blasts. We conclude that bisantrene does have an antileukemic effect, but that the optimal starting dose is not yet established. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|